Nuclear medicine for prostate cancer management.

[Nuclear medicine for prostate cancer management]. Prog Urol. 2019 Jun;29 Suppl 1:S2-S7 Authors: Erra B, Pradere B Abstract Nuclear medicine is a keystone specialty in the evaluation and management of prostate cancer. Its recent development, particularly through metabolic imaging and isotope therapy, has made it a major gamechanger in the management of metastatic prostate cancer. The aim of this article was to postpone its place within the various stages of the disease through a comprehensive review of national and international recommendations. PMID: 31307627 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research

Related Links:

Prebiopsy multiparametric magnetic resonance imaging (mpMRI) combined with targeted biopsy is associated with improved detection of clinically significant prostate cancer compared with transrectal ultrasonography-guided systemic biopsy alone, a systematic review and meta-analysis reveals.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
ConclusionsWe obtained health utility and HRQoL scores of Japanese PC patients stratified by disease progression in detail. Our results will be useful for establishing cost-effectiveness analyses in Japanese PC settings.
Source: Quality of Life Research - Category: Health Management Source Type: research
Publication date: Available online 16 August 2019Source: European UrologyAuthor(s): Adam W. Glaser
Source: European Urology - Category: Urology & Nephrology Source Type: research
The phase III PROSELICA trial showed that cabazitaxel 20 mg/m2 (C20) was not inferior and better tolerated compared to cabazitaxel 25 mg/m2 (C25) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed during or after docetaxel. Here, we report on a real-world retrospective analysis concerning the safety and the activity of C20 schedule in patients with mCRPC treated at our Institution. We identified 35 patients with mCRPC who received C20 as baseline dose treatment because they were frail or experienced serious toxicities to previous treatments. Adverse events assessment was performed a...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Papers Source Type: research
Authors: Cheung PK, Ma MH, Tse HF, Yeung KF, Tsang HF, Chu MKM, Kan CM, Cho WCS, Ng LBW, Chan LWC, Wong SCC Abstract Introduction: Metabolomics, the study of metabolites, is a promising research field for cancers. The metabolic pathway in a tumor cell is different from a normal tissue cell. There are two approaches to study the metabolism, targeted and untargeted. The general approach is that metabolomic data are interpreted by bioinformatics tools correlating with metabolomic databases to obtain significant findings. With the use of specific analysis tools, such as nuclear magnetic resonance (NMR) and mass spectro...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
Publication date: Available online 15 August 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of LipidsAuthor(s): Hudson W. Coates, Ngee Kiat Chua, Andrew J. BrownAbstractCholesterol accumulation is a hallmark of prostate cancer (PCa) enabled by upregulation of its synthesis, which presents a potential therapeutic target. This pathway is suppressed by the E3 ubiquitin ligase membrane-associated RING-CH-type finger 6 (MARCH6); however, little is known of MARCH6 regulation, particularly at the transcriptional level. Here, we consulted large transcriptomic PCa datasets to investigate transcription ...
Source: Biochimica et Biophysica Acta (BBA) Molecular and Cell Biology of Lipids - Category: Lipidology Source Type: research
The objective of this study was to determine whether osteoarthritis had an impact on outcomes of prostate cancer including death, local recurrence and/or metastasis and to determine whether cartilage oligomeric matrix protein was involved. We performed a retrospective case-control study of patients with prostate cancer with and without the diagnosis of osteoarthritis and completed immunohistochemistry (IHC) analysis of prostate (n=20) and lymph node (n=7) surgical specimens. We evaluated death, local recurrence and metastatic disease by various IHC biomarkers including prostate specific membrane antigen (PSMA), cartilage o...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: For studies and assessments requiring face-to-face contact, telehealth is clearly a feasible option for improving research representativeness and access for individuals residing in rural areas. Future research should make use of telehealth services, to give a voice to rural individuals who are too often left out. PMID: 31412701 [PubMed - in process]
Source: Rural and Remote Health - Category: Rural Health Tags: Rural Remote Health Source Type: research
Contributors : Wang Liang ; Xiao FankaiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensA prostate cancer risk single nucleotide polymorphism (SNP), rs13426236, is significantly associated with melanophilin (MLPH) expression. To functionally characterize role of the rs13426236 in prostate cancer, we first performed splicing-specific expression Quantitative Trait Loci (eQTL) analysis and refined the significant association of rs13426236 allele G with an increased expression of MLPH splicing variant 4 (V4) (P= 7.61E-5) but not other protein-coding variants (V1-V3) (P>0.05). We then pe...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
The ONE SHOT trial is the first phase I/II prospective, multicenter, single-arm study assessing the efficacy and safety of a single-dose SBRT for men with localized prostate cancer. Aim of this paper is to present the phase I results of a 19  Gy single fraction urethra-sparing SBRT with real-time electromagnetic tracking.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Short Communication Source Type: research
More News: Cancer | Cancer & Oncology | Nuclear Medicine | Prostate Cancer | Urology & Nephrology